Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the companion diagnostics market size evolved in recent years?
In recent times, there has been a notable expansion in the dimension of the companion diagnostics market. The market value which stood at $7.34 billion in 2024 is forecast to surge to $8.75 billion in 2025, marking a Compound Annual Growth Rate (CAGR) of 19.3%. Factors attributing to this trend during the historical period include a heightened usage of personalized medicine, the evolution in oncology and cancer treatments, increased collaborations in pharmaceutical research and development, initiatives geared towards precision medicine, and biomarker discovery.
What are the predictions for the companion diagnostics market size in the coming years?
In the forthcoming years, a significant expansion is projected for the companion diagnostics market. Predictions indicate that it will rise to $19.07 billion by 2029, with a compound annual growth rate (CAGR) of 21.5%. This growth during the forecast period can be linked to the developments in targeted therapy, diagnostics for infectious and rare diseases, the surge in biomarker-based drug development, point-of-care testing, and applications of liquid biopsy. Noteworthy trends for the forecast period encompass advances in immunology and immunotherapy, the incorporation of ai and machine learning in diagnostics, product innovations, as well as the adoption of industry 4.0 and strategic collaborations.
Get your companion diagnostics market report here!
https://www.thebusinessresearchcompany.com/report/companion-diagnostics-global-market-report
What key factors are fueling the growth of the companion diagnostics market?
The growth of the companion diagnostics market is poised to be driven by the increase in targeted therapies. These pharmacological treatments specifically address certain attributes of cancer cells, restraining disease proliferation and progression. Although these medicines travel through the body, their impact is more concentrated than chemotherapy, often leading to fewer side effects. The importance of biological marker-based companion diagnostic tests for targeted cancer therapy in personalized cancer treatment cannot be overstated. For example, the Personalised Medicine Coalition, a renowned health care organization based in the US, stated in February 2024 that the FDA greenlit 16 new personalized treatments for patients suffering from rare diseases in 2023 — a significant rise from just six in the previous year, 2022. This significant jump in targeted therapies is thus the driving force behind the expansion of the companion diagnostics market.
How is the global companion diagnostics market divided into key segments?
The companion diagnostics market covered in this report is segmented –
1) By Product And Service: Assays, Kits And Reagents, Software And Services
2) By Technology: Polymerase Chain Reaction, Next-Generation Sequencing, In Situ Hybridization, Immunohistochemistry
3) By Indication: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma
4) By End-User: Pharmaceutical And Biopharmaceutical Companies, Reference Laboratories, Contract Research Organizations
Subsegments:
1) By Assays: Polymerase Chain Reaction (PCR) Assays, Immunohistochemistry (IHC) Assays, Next-Generation Sequencing (NGS) Assays, In Situ Hybridization (ISH) Assays
2) By Kits And Reagents: Diagnostic Kits, Detection Reagents, Control Reagents
3) By Software And Services: Data Analysis Software, Interpretation Software, Custom Development Services, Consulting and Support Services
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=7038&type=smp
Who are the key firms paving the way for growth in the companion diagnostics market?
Major companies operating in the companion diagnostics market include F Hoffmann-La Roche Ltd., Agilent Technologies Inc., Qiagen NV, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Abnova Corp., Amoy Diagnostics Co. Ltd., ARUP Laboratories, Bayer AG, Biomerieux SA, Danaher Corporation, Guardant Health Inc., Illumina Inc., Myriad Genetics Inc., Siemens Healthcare GmbH, Almac Group, Caris Life Sciences, Cepheid Inc., Diaceutics plc, Epic Sciences Inc., Foundation Medicine Inc., Genomic Health Inc., Grail Inc., Hologic Inc., HTG Molecular Diagnostics Inc., Inivata Ltd., Invivoscribe Inc., MolecularMD Corporation, Natera Inc., NeoGenomics Laboratories Inc., Personal Genome Diagnostics Inc., Precision Therapeutics Inc., Prometheus Laboratories Inc., Sividon Diagnostics GmbH, Sysmex Corporation, Ventana Medical Systems, Vermillion Inc.
Which trends are expected to transform the companion diagnostics market?
Technological progress is a significant trend in the companion diagnostics sector. The use of artificial intelligence is increasingly common in creating more effective drugs for companion diagnostics. Large genetic profiling datasets, continuously collected, have allowed AI’s broad deployment. For instance, Deep Genomics, an innovative start-up from Toronto, leverages artificial intelligence to find more advanced treatments for genetic disorders and expedite their entry into clinical studies. The objective is to use advanced learning to delve into the human genome to understand disease origins and design and evaluate potential therapeutic chemical compounds. This advanced learning in a computational model allows scientists to explore billions of chemical compositions in pursuit of potential ones to be developed into life-saving medicines for global distribution.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7038
What regions are contributing significantly to the growth of the companion diagnostics market?
North America was the largest region in the companion diagnostics market in 2024. The regions covered in the companion diagnostics market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Similar Reports By The Business Research Company:
Interventional Oncology Devices Global Market Report 2024
Oncology Biosimilars Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report
Oncology Molecular Diagnostics Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
